Dr. Awasthi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6431 Fannin, H
MSB 1.150
Houston, TX 77030Phone+1 713-704-3961Fax+1 713-512-7132
Summary
- Dr. Sanjay Awasthi is an oncologist based in Houston, TX, with subspecialties in melanoma, neuro-oncology, and sarcoma. He completed his residency in internal medicine and a fellowship in hematology and medical oncology. Dr. Awasthi serves as Division Chief at Texas Tech Physicians and has held professorships at multiple institutions. His clinical experience spans breast and lung cancer, along with interests in cancer genetics and diabetes mellitus. He has contributed to several published works and has been involved in clinical trials, particularly in studying treatments for melanoma and bladder cancer. He has received numerous accolades, including being named a Regional Top Doctor and awarded by prominent organizations.
Education & Training
University of Texas Southwestern Medical CenterFellowship, Hematology and Medical Oncology, 1989 - 1991
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 1986 - 1989
University of Texas Southwestern Medical SchoolClass of 1986
The University of Texas at AustinB.A., Biochemistry, Cum Laude, 1982
Certifications & Licensure
TX State Medical License 1990 - 2025
CA State Medical License 2011 - 2017
AR State Medical License 1987 - 1992
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Young Scientist Award American Scientists of Indian Origin in America, 1996
- Oncology Training Fellowship Award American Cancer Society, 1990
- Join now to see all
Clinical Trials
- Studies on the Expression and Functions of RLIP76 in Blood Samples of Healthy Human Subjects Start of enrollment: 2008 Sep 01
- RLIP76 in Human Serum in Adults With Rheumatologic Diseases Start of enrollment: 2011 Sep 01
- Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2011 Jan 18
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsPhase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies.Alexis C Boulter, Barry J Maurer, Meredith Pogue, Min H Kang, Hwangeui Cho
Cancer Chemotherapy and Pharmacology. 2023-08-01 - 3 citationsThe innate effects of plant secondary metabolites in preclusion of gynecologic cancers: Inflammatory response and therapeutic action.Pankaj Garg, Sanjay Awasthi, David Horne, Ravi Salgia, Sharad S Singhal
Biochimica Et Biophysica Acta. Reviews on Cancer. 2023-07-01 - 2 citationsCase report of recurrent fibromatosis with laryngeal involvement: Treatment based on network analyses of NGS data.Nathan Lloyd, Jonathan Kopel, Sanjay Awasthi, Joehassin Cordero
Molecular and Clinical Oncology. 2022-03-01
Abstracts/Posters
- Incidence of Serious Adverse Events, Pneumonitis, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphom...Sanjay Awasthi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Daratumumab-Related Hematological Toxicities in Patients with Multiple Myeloma: A Combined Analysis of Five Phase III Randomized Controlled TrialsSanjay Awasthi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Performance of the New Automated Latex Immunoturbidometric Assay in the Diagnosis of Heparin Induced Thrombocytopenia: A Single Institution ExperienceSanjay Awasthi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
Govt-19 Vaccines Reach Migrant Workers in India Future PlanetAugust 19th, 2021
Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2018August 13th, 2018
Moleculin Biotech, Inc. Reports Financial Results for the First Quarter Ended March 31, 2018May 15th, 2018- Join now to see all
Grant Support
- Mechanism Of Drug Transport In Lung Cancer CellsNational Cancer Institute2011
- Mechanism Of Drug Transport In Lung Cancer CellsNational Cancer Institute2008–2011
- Role Of RALBP1 In Xenobiotic And Radiation ResistanceNational Cancer Institute2007–2008
- Role Of RALBP1 In Xenobiotic And Radiation ResistanceNational Cancer Institute2004–2007
- Mechanism Of Drug Transport In Lung Cancer CellsNational Cancer Institute1999–2007
- Glutathione Conjugates In Modulation Of Anthracycline Alkylating AgentNational Center For Research Resources1997–1999
- Mechanism Of Drug Transport In Lung Cancer CellsNational Cancer Institute1998
- Mechanism Of Doxorubicin Transport In Lung Cancer CellsNational Cancer Institute1994–1998
- Glutathione Conjugates In Modulation Of Anthracycline-Alkylating AgentNational Center For Research Resources1996
Professional Memberships
- Member
Other Languages
- Hindi, Urdu
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
